3-(4-amino-1-oxo-1 ,3-dihydroisoindol-2-yl)piperidine-2,6-dione-ammonium chloride | 1418206-00-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 3-(4-amino-1-oxo-1 ,3-dihydroisoindol-2-yl)piperidine-2,6-dione-ammonium chloride
• 英文别名: ammonium chloride lenalidomide；Lenalidomide ammonium chloride；azanium;3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione;chloride
• CAS: 1418206-00-4
• 化学式: C₁₃H₁₃N₃O₃*(x)ClH*(x)H₃N
• 分子量: 312.75
• InChiKey: LXTCNXYAIGZCLO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.59
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  93.5
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  来那度胺 在 氯化铵 作用下， 以 水 、 异丙醇 为溶剂， 反应 24.0h， 以10 mg的产率得到3-(4-amino-1-oxo-1 ,3-dihydroisoindol-2-yl)piperidine-2,6-dione-ammonium chloride
  参考文献：
  名称：

  [EN] NOVEL CRYSTALLINE FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE
  [FR] NOUVELLES FORMES CRISTALLINES DE 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOL-2-YL)PIPÉRIDINE-2,6-DIONE

  摘要：

  公开号：

  WO2013012485A3

文献信息

• Crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
  申请人：AMPLIO PHARMA, LLC

  公开号：US10100032B2

  公开（公告）日：2018-10-16

  The invention relates to novel crystalline forms of 3-(4-amino-l-oxo-l,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione, including a novel urea cocrystal of 3-(4-amino-l-oxo-l,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; a novel gallic acid cocrystal of 3-(4-amino-l-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; a novel propyl gallate cocrystal of 3-(4-amino-l-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; and a novel L-tartaric acid cocrystal of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione. The preparation and characterization of the novel crystalline forms according to various embodiments of the invention are described. The invention also relates to pharmaceutical compositions containing the novel crystalline forms, and the therapeutic use of the novel crystalline forms.

  本发明涉及 3-(4-氨基-1-氧代-1,3-二氢-异吲哚-2-基)-哌啶-2,6-二酮的新型结晶形式，包括 3-(4-氨基-1-氧代-1,3-二氢-异吲哚-2-基)-哌啶-2,6-二酮的新型脲共晶体；3-(4-氨基-l-氧代-1,3-二氢-异吲哚-2-基)-哌啶-2,6-二酮的新型没食子酸共晶体； 3-(4-氨基-l-氧代-1,3-二氢-异吲哚-2-基)-哌啶-2,6-二酮的新型没食子酸丙酯共晶体；以及 3-(4-氨基-1-氧代-1,3-二氢-异吲哚-2-基)-哌啶-2,6-二酮的新型 L-酒石酸共晶体。本发明描述了根据本发明各种实施方案制备的新型晶体的制备和表征。本发明还涉及含有新型结晶形式的药物组合物以及新型结晶形式的治疗用途。
• NOVEL CRYSTALLINE FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE
  申请人：AMPLIO PHARMA, LLC

  公开号：US20140296291A1

  公开（公告）日：2014-10-02

  The invention relates to novel crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione, including a novel urea cocrystal of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; a novel gallic acid cocrystal of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; a novel propyl gallate cocrystal of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; and a novel L-tartaric acid cocrystal of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione. The preparation and characterization of the novel crystalline forms according to various embodiments of the invention are described. The invention also relates to pharmaceutical compositions containing the novel crystalline forms, and the therapeutic use of the novel crystalline forms.
• US9540341B2
  申请人：——

  公开号：US9540341B2

  公开（公告）日：2017-01-10